News

IDEAYA Biosciences Advances IND Submission for IDE892 Trial

IDEAYA Biosciences Advances IND Submission for IDE892 Trial

IDEAYA Biosciences Submits IND Application for IDE892

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a pioneering company in precision medicine for oncology, has made an important step forward by submitting an investigational new drug (IND) application for IDE892. This promising compound is designed to be a leading MTA-cooperative inhibitor of PRMT5, specifically targeting MTAP-deleted solid tumors.

Phase 1 Clinical Trial Plans

The company plans to initiate a Phase 1 dose escalation trial of IDE892, focusing on patients with MTAP-deleted lung cancer, aiming to begin in the fourth quarter of 2025. Following this, IDEAYA looks to move forward into exciting combination trials that would integrate IDE892 with IDE397, their distinct and proprietary MAT2A inhibitor, targeted for the first half of 2026.

The Significance of MTAP-Deletion in Cancer

Research indicates that approximately 15-20% of cases of non-small cell lung cancer (NSCLC) exhibit MTAP-deletion. This genetic alteration leads to an elevated ratio of MTA/SAM, creating a unique vulnerability in these cancers for therapies targeting PRMT5. When combined with MAT2A inhibition, the tumor-specific benefits enhance, making the potential therapy even more attractive. IDEAYA aims to explore additional solid tumor opportunities as part of their clinical evaluation involving both IDE892 alone and in partnership with IDE397.

Insights from Leadership

Michael White, Chief Scientific Officer at IDEAYA Biosciences, expressed enthusiasm about the advancement of IDE892 into clinical trials for MTAP-deleted lung cancer patients. He believes that combining PRMT5 inhibition with MAT2A could produce powerful synergistic effects against tumors. IDE892’s development reflects IDEAYA’s commitment to optimizing its biophysical and pharmacokinetic properties, ultimately aiming to establish it as a best-in-class therapy in this category.

10-Year Anniversary R&D Day Announcement

IDEAYA will present the preclinical profile of IDE892 alongside the combination rationale with IDE397 at their upcoming 10-Year Anniversary R&D Day. This event promises to showcase groundbreaking research and insights into their innovative approaches to oncology.

About IDEAYA Biosciences

IDEAYA is dedicated to developing cutting-edge therapies for cancers through precision medicine. They focus on small-molecule drug discovery, and their methodology combines structural biology and bioinformatics to identify and validate vital biomarkers. This allows them to create targeted therapies that align with the genetic underpinnings of various cancers. The company has an impressive pipeline, emphasizing synthetic lethality and antibody-drug conjugates aimed at well-defined solid tumor indications.

Conclusion

As IDEAYA advances with the IND submission for IDE892, the excitement within the oncology community grows. With a focused commitment to addressing significant unmet needs through innovative therapies, IDEAYA Biosciences is set to continue making impactful strides in cancer treatment.

Frequently Asked Questions

What is the purpose of the IND submission for IDE892?

The IND submission is aimed at seeking approval to begin clinical trials for IDE892, targeting specific cancer types.

When is the Phase 1 trial for IDE892 expected to start?

The Phase 1 trial is planned to initiate in the fourth quarter of 2025.

What is MTAP-deletion and why is it significant?

MTAP-deletion is a genetic alteration found in some lung cancers that provides a specific vulnerability to PRMT5 inhibitors, making it a target for teletherapeutics.

How does IDE892 relate to IDE397?

IDE892 is being developed to work in conjunction with IDE397, potentially enhancing antitumor activity.

What initiatives is IDEAYA focusing on for the future?

IDEAYA aims to advance its pipeline of therapies while focusing on targeted cancer treatments aligned with genetic drivers in solid tumors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 226

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 174

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 116

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 93

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work

Updated Category News Views 62

A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 167

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 49

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 30

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 201

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading

Top 5 Most Recently Viewed Articles

ChargePoint Faces Share Decline Following Q2 Financial Report

Updated Category News Views 67

Overview of ChargePoint's Stock Performance ChargePoint Holdings Inc (NYSE: CHPT) has seen a drop in its stock value following the release of disappointing financial results for the second quarter. Investors are carefully examining the details of the report, which highlighted significant challenges the company faced during this time. Q2 Financial Highlights In the second...

Continue Reading
Exciting March Madness Audio Coverage by Westwood One 2025

Updated Category News Views 244

Comprehensive Audio Coverage of NCAA Men's Basketball Tournament As the NCAA Men's Basketball Tournament approaches, fans are gearing up for what promises to be an exciting series of games. This year, Cumulus Media's Westwood One (NASDAQ: CMLS) will provide exclusive multiplatform audio coverage of the entire tournament, ensuring that fans can enjoy every moment, whether...

Continue Reading
Cartesian Therapeutics Advances Myasthenia Gravis Treatment Trials

Updated Category News Views 118

Advancements in Myasthenia Gravis Treatment by Cartesian Therapeutics Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a pioneering company in mRNA cell therapy, is making significant strides in developing groundbreaking treatments for autoimmune diseases, especially myasthenia gravis (MG). With encouraging updates from the Phase 2b trial of their leading candidate,...

Continue Reading
Centrifuge Market Set to Surpass $689 Million Amid Growth

Updated Category News Views 147

Growth of the Centrifuge Market: An In-Depth Analysis The centrifuge market is undergoing a remarkable transformation, with projections indicating an increase from USD 463 million in 2023 to an impressive USD 689.91 million by 2032. This growth is driven by a compound annual growth rate (CAGR) of 4.53% from 2024 to 2032, fueled by advancements in biotechnology,...

Continue Reading
National Bank Holdings Sees Price Target Increase by Piper Sandler

Updated Category News Views 58

Piper Sandler Raises Price Target for National Bank Holdings Piper Sandler has recently reviewed its financial outlook for National Bank Holdings (NYSE: NBHC), making a significant update to its price target. The new target has been set at $48.00, an increase from the previous target of $44.00. Current Stock Rating and Rationale The firm has maintained a Neutral rating on...

Continue Reading